NANOPARTICLES

摘要

A patient with HIV in the UK usually takes two pills every day, for life - that is 730 pills a year. Although the pill burden for HIV patients has come down significantly, adherence is still an issue. Patients taking a single tablet regimen achieve 95% adherence around 25% of the time and patients on a two-tablet regimen only 17% of the time (Nat Commun, online 21 October 2016). For young children with HIV, adult formulations can also be less than ideal because they contain 'harsh organic solvents', says Andrew Owen (pictured), a molecular and clinical pharmacologist at the University of Liverpool. He believes nanotechnology could provide the solution.